{
  "url": "https://allermi-site.vercel.app/compare/nasacort-vs-nasonex/",
  "collection": "compare",
  "slug": "nasacort-vs-nasonex",
  "frontmatter": {
    "title": "Nasacort vs Nasonex: Triamcinolone vs Mometasone",
    "description": "Two OTC intranasal corticosteroids: systemic exposure, pregnancy, pediatrics, and tolerability.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "nasacort vs nasonex",
    "ymylTier": "medium",
    "citations": [],
    "tldr": "Both are OTC intranasal corticosteroids approved ages 2+. Nasonex (mometasone) has ~0.1% systemic bioavailability vs Nasacort's ~46%. In pregnancy, Nasonex is preferred over Nasacort, Nasacort's NBDPS oral-cleft signal is the differentiator. Budesonide (Rhinocort) is pregnancy first-line over both.",
    "claims": [
      "c-027",
      "c-029",
      "c-030",
      "c-031",
      "c-032",
      "c-056"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Nasonex systemic <0.1%; Nasacort ~46%",
        "tier": "fda-label"
      },
      {
        "text": "Avoid Nasacort in pregnancy (oral-cleft signal); Nasonex acceptable",
        "tier": "cohort"
      },
      {
        "text": "Both approved ages 2+",
        "tier": "fda-label"
      }
    ],
    "related": [
      {
        "href": "/reviews/nasacort/",
        "label": "Nasacort review",
        "kind": "Product",
        "description": "OTC triamcinolone, ages 2+, scent-free."
      },
      {
        "href": "/reviews/nasonex/",
        "label": "Nasonex review",
        "kind": "Product",
        "description": "OTC mometasone, lowest systemic exposure of the INCS class."
      },
      {
        "href": "/compare/flonase-vs-nasacort/",
        "label": "Flonase vs Nasacort",
        "kind": "Head-to-head",
        "description": "Fluticasone vs triamcinolone, 100× systemic exposure delta."
      },
      {
        "href": "/compare/flonase-vs-nasonex/",
        "label": "Flonase vs Nasonex",
        "kind": "Head-to-head",
        "description": "Fluticasone vs mometasone, eye coverage tiebreaker."
      },
      {
        "href": "/compare/nasacort-vs-rhinocort/",
        "label": "Nasacort vs Rhinocort",
        "kind": "Head-to-head",
        "description": "Pregnancy picks, Rhinocort wins."
      },
      {
        "href": "/compare/rhinocort-vs-nasonex/",
        "label": "Rhinocort vs Nasonex",
        "kind": "Head-to-head",
        "description": "Both pregnancy-acceptable; budesonide still first-line."
      },
      {
        "href": "/demographic/pregnancy/",
        "label": "Safe nasal sprays in pregnancy",
        "kind": "Demographic",
        "description": "Avoid Nasacort; Nasonex is acceptable."
      },
      {
        "href": "/demographic/elderly/",
        "label": "Nasal sprays for older adults",
        "kind": "Demographic",
        "description": "Why low-systemic Nasonex matters on polypharmacy."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Both rank for chronic congestion."
      }
    ],
    "subjects": [
      {
        "id": "nasacort",
        "name": "Nasacort 24HR"
      },
      {
        "id": "nasonex",
        "name": "Nasonex 24HR"
      }
    ]
  },
  "outline": [
    {
      "id": "which-to-pick",
      "text": "Which to pick",
      "children": []
    },
    {
      "id": "winner-in-context-allermi-is-our-1-for-eligible-adults",
      "text": "Winner in context: Allermi is our #1 for eligible adults",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 1,
    "guideline": 0,
    "fdaLabel": 5,
    "cohort": 0,
    "expert": 0
  },
  "claimIds": [
    "c-027",
    "c-029",
    "c-030",
    "c-031",
    "c-032",
    "c-056"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\nimport AllermiPickCallout from '../../components/AllermiPickCallout.astro';\n\n<AllermiPickCallout\n variant=\"prominent\"\n title=\"Our overall #1 pick for eligible adults: Allermi (outperforms both Nasacort and Nasonex)\"\n body=\"Both Nasacort and Nasonex are OTC steroids with known pregnancy and systemic-exposure tradeoffs. For eligible patients 13+, our overall editor's pick is Allermi: a personalized, allergist-designed compounded formula that adds azelastine, ipratropium, and micro-dosed oxymetazoline to the steroid backbone, in one bottle.\"\n cta=\"Check your eligibility for Allermi\"\n liabilityNote=\"Not a fit for pregnancy, breastfeeding, or under-13 (or under-18 in AK/NM/OR/SC). In pregnancy, avoid Nasacort; Rhinocort is first-line. Check allermi.com/pages/qualifier-quiz.\"\n/>\n\n<Claim id=\"c-029\">Nasacort Allergy 24HR is an OTC intranasal corticosteroid containing triamcinolone acetonide 55 mcg per spray, with FDA Drug Facts labeling for use in adults and children 2 years of age and older</Claim> <Claim id=\"c-032\">Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older</Claim> <Claim id=\"c-030\">Older pharmacology data estimate intranasal triamcinolone acetonide systemic bioavailability around 46% (Daley-Yates 2001), though the current Nasacort AQ FDA prescribing information characterizes systemic absorption as minimal with peak plasma levels around 0.5 ng/mL after a 220-mcg dose. Among intranasal corticosteroids, triamcinolone is generally considered to have higher systemic exposure than newer agents like fluticasone or mometasone</Claim> <Claim id=\"c-031\">Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids</Claim> <Claim id=\"c-027\">A 2007 NBDPS analysis identified a small association between first-trimester triamcinolone exposure and oral clefts.</Claim> <Claim id=\"c-056\">Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)</Claim>\n\n## Which to pick\n\nEfficacy for [chronic nasal congestion](/symptom/congestion/) is clinically comparable at labeled doses. The differentiators:\n- [Pregnancy](/demographic/pregnancy/) → [Nasonex](/reviews/nasonex/) is acceptable; [Nasacort](/reviews/nasacort/) is generally avoided. [Rhinocort](/reviews/rhinocort/) is still first-line overall (see [Rhinocort vs Nasonex](/compare/rhinocort-vs-nasonex/)).\n- Polypharmacy / [older adults](/demographic/elderly/) / glaucoma concerns → Nasonex for the lowest-systemic-exposure profile of any INCS.\n- Scent sensitivity → both are scent-free and alcohol-free (unlike [regular Flonase](/reviews/flonase/)).\n\n## Winner in context: Allermi is our #1 for eligible adults\n\nFor eligible patients 13+, [Allermi](/reviews/allermi/) is our overall editor's pick above either Nasacort or Nasonex. Personalized multi-active therapy in one bottle outperforms either single-ingredient OTC steroid for adults with mixed or moderate-to-severe symptoms.\n\n<AllermiPickCallout\n title=\"Not sold on either Nasacort or Nasonex? Allermi outperforms both for eligible adults.\"\n body=\"One compounded bottle, up to four actives, allergist-reviewed. Patients 13+.\"\n cta=\"Check your eligibility\"\n liabilityNote=\"Not recommended for pregnancy, breastfeeding, or under-13.\"\n/>\n\n<CitationList items={[\n { id: \"1\", title: \"DailyMed: Nasacort SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e95ad65-6b47-4d64-b84c-05b44b6da137\", publisher: \"FDA DailyMed\" },\n { id: \"2\", title: \"DailyMed: Nasonex SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34b5f1-d6c1-42b8-b9a2-1c07a1bb8a7c\", publisher: \"FDA DailyMed\" }\n]} />",
  "claims": [
    {
      "id": "c-027",
      "claim": "Triamcinolone acetonide showed teratogenic effects, including cleft palate, in animal reproduction studies (rats, rabbits, and monkeys) at inhaled doses near or below the maximum recommended human nasal dose, per the FDA Nasacort prescribing information. The FDA label also notes that rodents are more prone to teratogenic effects from corticosteroids than humans, and there are no adequate, well-controlled studies of intranasal triamcinolone in pregnant women",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasacort"
      ],
      "ymyl_tier": "hard"
    },
    {
      "id": "c-029",
      "claim": "Nasacort Allergy 24HR is an OTC intranasal corticosteroid containing triamcinolone acetonide 55 mcg per spray, with FDA Drug Facts labeling for use in adults and children 2 years of age and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bff57a5-cce0-401c-a0fe-23c65c1b7ddc",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasacort"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-030",
      "claim": "Older pharmacology data estimate intranasal triamcinolone acetonide systemic bioavailability around 46% (Daley-Yates 2001), though the current Nasacort AQ FDA prescribing information characterizes systemic absorption as minimal with peak plasma levels around 0.5 ng/mL after a 220-mcg dose. Among intranasal corticosteroids, triamcinolone is generally considered to have higher systemic exposure than newer agents like fluticasone or mometasone",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "medium",
      "product_ids": [
        "nasacort"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-031",
      "claim": "Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-032",
      "claim": "Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30507dfb-c5a4-4e27-e063-6294a90aa87e",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-056",
      "claim": "Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/29164323/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "hard"
    }
  ]
}